Reading GALT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GALT free→Reading GALT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GALT free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, which may impact future performance. If GALT cuts guidance on the next call, that's a meaningful negative, as the Street tends to walk down estimates and the stock usually takes a leg lower. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $2.62. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.76x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.07 → $-0.09 (-28.6% / 30d). 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$287.
How much price usually moves either way.
On a bad day, this stock has moved -$869.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,805.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for GALT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 15, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histor…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
GALT Galectin Therapeutics Inc | — | — | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Ensure the company has enough cash to fund planned operations and R&D activities through May 2027.
Newly stated in 2026-Q1. The company has declared it has enough cash to support its operations and R&D activities through May 2027. However, the financials show a net income loss of $5.05 million in 2026-Q1, indicating ongoing financial challenges. The trajectory is uncertain given the current losses.
“The Company believes it has sufficient cash to fund currently planned operations and research and development activities through May 2027.”
Access a $10 million line of credit to finance working capital needs.
Newly stated in 2025-Q4. The company secured a $10 million line of credit to support working capital. Despite this, the financials reveal a net income loss of $5.5 million in 2025-Q4, suggesting the line of credit is crucial for liquidity. The trajectory is dependent on effective utilization of this credit.
“Entered into a Line of Credit Letter Agreement... provide the Company a line of credit of up to $10.00 million.”
Results of Operations and Financial Condition. On March 31, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2026, the Board of Directors of Galectin Therapeutics Inc. (the “Company”) appointed Dr. Henry Brem to serve as a member of the Board of Directors, effective immediately. Dr. Brem was not appointed pursuant to any arrangement or understanding with any other person. There are no transactions between Dr. Brem and the Company that would b…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 16, 2026, at the recommendation of the Company’s compensation committee, the Company’s board of directors approved a $300,000 cash retention bonus for the Company’s Chief Medical Officer, Dr. Khurram Jamil, and a $150,000 cash retention bonus for the Company’s Chief Financial Officer, Jack Callicutt. The retention bonuses will be paid in…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2026, Marc Rubin resigned from the Board of Directors of Galectin Therapeutics, Inc. (the “Company”). Mr. Rubin’s resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin…